Risk Factors Update Summary

• Added risks related to reputation and prospects, including the introduction of new products and indications.
• Added risks related to intellectual property, including challenges from generic pharmaceutical companies and potential patent infringements.
• New regulations with short notice may hinder business objectives, be costly, and carry penalties.
• Increased the percentage of total revenue from key products, with Trulicity and Mounjaro showing significant changes.
• Noted the challenges in drug discovery and development, emphasizing the high rate of failure.
• Highlighted the risks associated with the use of artificial intelligence and emerging technologies in operations.
• Regulatory oversight may be particularly unpredictable, leading to additional costs, uncertainties, and risks.
• Highlighted the importance of maintaining a continuous flow of successful new products and indications.
• Addressed uncertainties in drug approval processes across markets and agencies, leading to delays in product launches.
• Emphasis on sustainability, brand, and reputation protection to avoid negative impacts and enforcement actions.